Acorda Therapeutics, of Hawthorne, N.Y., promoted Andrew Blight to chief scientific officer and Mary Fisher to executive vice president of operations.
Adventrx Pharmaceuticals Inc., of San Diego, appointed Edward Ball to its scientific advisory board.
AtheroGenics Inc., of Atlanta, appointed Charles Montgomery vice president of business development.
AusAm Biotechnologies Inc., of Santa Monica, Calif., appointed Glenn Sherman to its board.
Evotec OAI AG, of Hamburg, Germany, appointed Mark Ashton president of drug discovery services and Mario Polywka president of chemical and pharmaceutical development. Ian Hunneyball will become president of the company's discovery programs division and chief scientific officer.
Dendreon Corp., of Seattle, appointed Richard Brewer to its board.
DermTech International, of San Diego, appointed Gail Naughton to its board.
Dyadic International Inc., of Jupiter, Fla., appointed Richard Lerner chairman of its scientific advisory board.
Exten Industries Inc., of Warwick, R.I., promoted Ronald Faris to chief science officer.
Generex Biotechnology Corp., of Toronto, appointed Douglas Powell director of immunobiology at its Boston subsidiary, Antigen Express.
GTx Inc., of Memphis, Tenn., appointed Greg Deener director of marketing and sales.
Helix BioMedix Inc., of Bothell, Wash., appointed David Drajeske director of business development.
Forbes Medi-Tech Inc., of Vancouver, British Columbia, added Steven Nissen, Thomas Pearson, Daniel Rader and Steven Haffner to its scientific advisory board.
GeneGo, of St. Joseph, Mich., appointed Sean Ekins vice president for computational biology.
Genstruct Inc., of Cambridge, Mass., appointed Douglas Lauffenburger to its board.
Introgen Therapeutics Inc., of Houston, elected Malcolm Gillis to its board.
Invitrogen Corp., of Carlsbad, Calif., appointed Michael Stapleton general manager and vice president and Vivien Bonazzi director of research and development, both at its bioinformatics business.
Large Scale Biology Corp., of Vacaville, Calif., said its wholly owned subsidiary, Eclipse Diagnostics Inc., appointed John Rakitan senior vice president and general manager, Gary Wolfe senior vice president and chief scientific officer, Guy della Cioppa senior vice president of business development and Ronald Artale senior vice president and chief financial officer. Kevin Ryan, president and CEO of Large Scale, will serve as president of Eclipse, while John Chute was appointed to the scientific advisory board.
Luminex Corp., of Austin, Texas, named David Reiter vice president, general counsel and corporate secretary.
Lynx Therapeutics Inc., of Hayward, Calif., appointed Susan Berland acting chief financial officer.
Merck KgaA, of Darmstadt, Germany, named Paul Breddels head of the liquid crystals division and Henryk Klakurka head of the generics division.